header-2.jpg
Translational Research

Presentations 2015

In 2015, APCRC-Q research fellows and students presented orals and posters at the following national and international conferences:

The Brisbane Cancer Conference, Brisbane, 17-19 December 2015:

Plenary Lecture: Richard D. DNA repair.
Plenary Lecture: Yates P. Patient outcomes research.
Plenary Lecture: O’Byrne K. Targeted therapies in malignant disease.
Workshop: Yates P. TrueNTH Survivorship Program.
Workshop: Williams ED. Modeling osteosclerotic metastases ex-vivo.
Workshop: Russell P. Understanding prostate cancer and how it informs imaging and therapy.
Workshop: Tse B. Pre-clinical Imaging.

TRI Cancer Seminar, 10 December 2015

Oral: Batra J. Prostate Cancer in the post-GWAS era

6th Annual IHBI Early Career Researcher Symposium, Brisbane, 4 December 2015

Poster: Pandey S, Walpole C, Cabot PJ, Shaw PN, Batra J, Hewavitharana AK. Separation and identification of fraction(s) from Carica papaya leaf showing selective anti-cancer activity on prostate cancer.

Epithelial Mesenchymal Transitions and Cancer Symposium, Cancer Research Institute of Kanazawa University, Japan, 30 November 2015.

Invited speaker: Williams ED. Molecular and cellular mechanisms driving prostate cancer progression. 

International Symposium on Functional Nucleic Acids: From Laboratory to Targeted Molecular Therapy, Perth, 26–27 November 2015.

Invited speaker: Thomas P, Walpole CM, Jeffery PL, Jovanovic L, Herington AC, Nelson CC, Whiteside EJ, Veedu RN, Seim I, Chopin LK. The ghrelin receptor antisense long non-coding RNA, GHSROS, regulates prostate cancer growth and survival and can be targeted with a locked antisense oligonucleotide.

The Prostate Cancer Collaborative Research Symposium, Brisbane, 25–28 November 2015:

Oral: Volpert M. Targeting Neuropilin-1 to inhibit prostate cancer metastasis and therapy resistance.

Oral: Gunter J. Targeting metabolic drivers of prostate cancer resistance and survival.

Oral: Sadowski M. Inhibition of de novo fatty acid synthesis suppresses androgen signalling in prostate cancer.

Oral: Philp L. Leptin: Classical adipokine peptide hormone controlling systemic energy balance – a role in advanced prostate cancer?

Oral: Levrier C. Investigation in prostate cancer cells of a new mitotic inhibitor isolated from an Australian endemic rainforest tree.

Oral: Tse B. Imaging prostate cancer with multimodal hyperbranched polymers targeting prostate specific membrane antigen (PSMA).

Oral: Chopin LK. Targeting the long non-coding RNA GHSROS, a mediator of prostate cancer tumour growth, with short antisense oligonucleotides.

Oral: Yeh M-C. Glypican-1: a new biomarker for detection of prostate cancer.

Oral: Soekmadji C. Assessment of extracellular vesicles for prognostic biomarkers in advanced prostate cancer.

Oral: Lehman M, Team transcriptomics.

Oral: Wang C. Weighted gene co-expression in network analysis using RNA-Seq data.

Oral: Batra J. SNP bases to basis of prostate cancer in post GWAS era.

Oral: Tevz G. Identification of a novel RLN1-RLN2 fusion transcript in prostate cancer.

Oral: Sweeney K. The role of ZEB1 in ATT-induced cellular plasticity.

Oral: Hollier B. Revealing the transcriptional landscape of epithelial-mesenchymal plasticity in prostate cancer progression.

Oral: Martine L. A tissue engineering approach to develop humanised mice models of bone metastasis.

Oral: Williams E. Modelling prostate cancer-induced formation in vitro.

Oral: Clements J. Proteases as key drivers of prostate cancer progression.

Oral: Vela I. Integrating multidisciplinary team management.

Oral: Keogh J. Sarcopenia: its effects and treatment options.

Oral: Rhee H. Implications of molecular imaging on modern day prostate cancer management: Diagnosis, Treatment and Follow Up.

Oral: Russell P. New approaches to combined imaging and therapy for prostate cancer.
Oral: Vela I. CTC and organoid in vitro culture technology in advanced prostate cancer precision medicine.

Poster: An J, Lai J, Wang C, Tevz G, Lehman ML, Nelson CC. Visualization of next generation sequencing data.  

Poster: Sarkar P, Gunter J, Lubik A, Stylianou N, Hollier B, Pollak M, Williams E, Nelson C. Insulin increases invasion in androgen deprived prostate cancer cells by activating EMT like changes.

Poster: Stylianou N, Lehman ML, Wang C, Jovanovic L, Rockstroh A, Kashyap A, Mani SA, Westbrook TF, Williams ED, Gunter JH, Nelson CC, Hollier BG. MErT is enriched in lethal metastatic castrate resistant prostate cancer and correlates with an overall poor prognosis across multiple cancers.

Poster: Tevz G, Hossain AM, Bock N, Jeet V, Bathgate RA, Williams ED, Lehman M, Hutmacher DW, Wade JD, Nelson CC. Impeding the adaptive response of prostate cancer to androgen targeted therapies with relaxin receptor antagonist.

Poster: Maugham M, Thomas P, Crisp G, Seim I, Chen C, Gregory L, Nelson C, Jeffery P, Chopin L. Modelling metabolic syndrome in immunodeficient mice.

Poster: Kryza T, Tevz G, McPherson S, Lehman M, Stephens C, Hollier B, Nelson C, Clements J. Dysregulation of the proteolytic network in prostate cancer cells after androgen deprivation and androgen-targeting therapies.

Poster: Sadowski M, Rockstroh A, Soekmadji C, McPherson SJ, Tevz G, Gunter JH, Jeet V, Nelson CC. Phenotypic and molecular analysis of androgen receptor signalling in the DuCaP prostate cancer cell line.

Poster: Sadowski M, Gunter JH, Gupta R, Blanksby SJ, Nelson CC. Investigation of deregulated lipid metabolism in advanced prostate cancer.

Poster: Sadowski M, Pouwer R, Lubik AA, McPherson S, Nelson CC. Evaluation of the fatty acid synthase inhibitor triclosan in prostate cancer cells.

Poster: Sadowski M, Lubik AA, Nelson CC. Inhibition of fatty acid synthase suppresses androgen signalling in LNCaP cells.

Poster: Liberio M, Sadowski MC, Rockstroh A, Davis RA, Nelson CC. BDX-1: A natural small molecule activator of the amino stress response pathway in prostate cancer cells.

Poster: Liberio MS, Sadowski MC, Rockstroh A, Vasireddy R, Davis RA, Nelson CC. The ascidian natural product EB activates DNA damage response pathways through inhibition of topoisomerase II in LNCaP cells.

Poster: Upadhyaya A, Stylianou N, Hollier BG, Davies A, Ryan SL, Williams ED, 2D and 3D models for evaluating the effect of Epithelial to Mesenchymal plasticity on chemoresistance in prostate cancer.

Poster: Tse BW-C, Fuchs AV, Pearce A, Yeh M-C, Fletcher N, Huang SS, Heston WDW,  Whittaker AK, Thurecht KJ, Russell PJ, Multimodal hyperbranched polymers for prostate cancer theranostics.

Poster: Walpole C, Rae F, Jovanovic L, Odorico D, McLennan E, Lawrence M, Nelson C, Williams ED, Batra J, Clements J. Characterisation of novel primary tumour derived epithelial prostate cancer cell lines.

Poster: Soekmadji C, Ruelcke J, Wang C, Riches JD, McPherson S, Russell PJ, Hill MM, Jenster GW, Nelson CC. Extracellular vesicles mediate paracrine signalling in androgen deprived prostate cancer.

Poster: Levrier C, Sadowski MC, Davis RA, Nelson CC. Investigation in prostate cancer cells of a new mitotic inhibitor isolated from an Australian endemic rainforest tree.

Poster: Mosaad E, Futrega K, Chambers K, Clements J, Doran M. Rethinking stromal cells contribution in the drug screening approach of prostate cancer.

Poster: Matin F, Jeet V, Moya L, Clements J, Batra J, MicroRNAs in plasma: potential minimally invasive biomarkers for the detection of aggressive prostate cancer.

Poster: Tevz G, McGrath S, Rockstroh A, Jeet V, McPherson S, Lehman M, Lai J, Batra J, An J, Williams E, Nelson C. Identification of a novel fusion transcript between human relaxin-1 (RLN1) and human relaxin-2 (RLN2) in prostate cancer.

Poster: Gunter JH, Lee W, Philp L, Sarkar P, Hollier B, Sadowski M, Lehman M, Nelson CC. Insulin increases apoptotic resistance in prostate cancer cells, but are sensitised by metformin.

Poster: Lisle J, Maharaj M, Mertens-Walker I, Stephens C, Stansfield S, Herington A, Clements J, Stephenson S-A, Proteolysis regulates the EphB4 receptor in prostate cancer.
Poster: Sweeney K, Stylianou N, Tevz G, Pirlo K, Upadhyaya A, Lehman M, Fazli L, Gleave M, Gunter J,Williams ED, Nelson CC, Hollier BG. Elucidating the role of ZEB1 in metastatic castration resistant prostate cancer.  

Poster: Philp L, Sadowski MC, Gunter JH, Tevz G, Liberio M, Lehman M, Otvos L, Nelson C. Leptin Receptor Antagonist, Allo-Aca, Prevents Leptin-Stimulated Migration and Invasion of Androgen-Deprived Prostate Cancer Cells.

Poster: Volpert M, Tse B, Ratther E, Stylianou N, Nouri M, Roshan-Moniri M, Butler M, Caradec J, Gregory-Evans C, Lehman M, Takhar M, Erho N, Alshalafa M, Davicioni E, Jenkins R, Karnes J, Den R, Fazli L, Gleave M, Williams E, Rennie P, Buttyan R, Gunter J, Russell P, Nelson C, Hollier B, Targeting Neuropilin-1 to inhibi prostate cancer metastasis and therapy resistance.

Poster: Thomas PB, Walpole CM, Jeffery PL, Jovanovic L, Herington AC, Nelson CC, Whiteside EJ, Veedu RN, Seim I, Chopin LK, Targeting the long non-coding RNA GHSROS, a mediator of prostate cancer growth, with short antisense oligonucleotides.

Poster: Yeh M-C, Jeet V, Wissmueller S, Campbell DH, Walsh BJ, Nelson CC, Russell PJ, Glypican-1: a new biomarker for the detection of prostate cancer.

Poster: Maharaj M, Mertens-Walker I, Stephens C, Croll T, Lisle J, Sagar Y, Walsh T, Herington A, Stephenson S-A, SUMOylation regulates the stabiloity of the receptor tyrosine kinase, EphB4.

Poster: Hu Q, Sweeney K, Russell PJ, Williams ED, Nelson CC, Hollier BG Non-Invasive Photoacoustic and Ultrasound Monitoring of Prostate Tumour Responses to Androgen Targeted Therapies.

Poster:  Ratther E, Sweeney K, Stylianou N, Tevz G, Nelson CC, Williams ED, Hollier BG Characterising neuroendocrine transdifferentiation in the progression to castration resistant prostate cancer.

Poster: Pandey S, Walpole C, Cabot PJ, Shaw PN, Batra J, Hewavitharana AK, Carica papaya leaf juice extracts have selective anti-proliferative responses in prostatic disease.

Poster: Srinivasan S, Stephens C, Clements J, Batra J, Functional validation of PSA coding variants associated with prostate cancer risk.

Poster: Subramaniam S, Walpole C, Clements J, Batra J, Allele specific regulation of PDK1 and MCAT by miRNAs.

Poster: Kryza T, Fuhrman-Luck R, Stephens C, Loessner D, Clements J. The kallikrein-related peptidase 4 is involved in activation of prostate-derived stromal cells through the protease-activated receptor-1.

Poster: Jeet V, Rockstroh A, Lehman M, Nelson C, Investigating the role of a potential angiogenic target, YKL40, for the treatment of metastatic prostate cancer.

Poster: Sagar Y, Maharaj M, Herington A, Thier R, Stephenson S-A, The involvement of glutathione transferases and exosomes in regulating progression and metastasis of prostate cancer.

Poster: Kedda M-A, Pryor D, Nelson C, The Prostate Cancer Outcomes Registry – Queensland.

Poster: Fung M, Rhee H, Heathcote P, Wood S, Greenslade S, Shepherd B, Lampe G, Thomas P, Vela I, Russell P, Ho K, Gunter J, Nelson C. Clinical studies at the Australian Prostate Cancer Research Centre – Queensland.

Poster: Yeadon T, A decade of success for the Australian Prostate Cancer BioResource.

The IHBI Inspires Postgraduate Student Conference, Brisbane, 17-20 November 2015:

Oral: Sarkar P. Insulin increases invasion in androgen deprived prostate cancer cells by activating EMT-like changes.

Oral: Srinivasan S. Prostate cancer risk associated PSA germline variants regulate PSA protease function.

Oral: Matin F. MicroRNAs in plasma: Potential minimally invasive biomarkers for the detection of aggressive prostate cancer.

Poster: Stylianou N, Lehman M, Wang C, Jovanovic L, Rockstroh A, Sadowski MC, Kashyap A, Mani SA, Westbrook TF, Williams ED, Gunter JH, Nelson CC, Hollier BG, Investigating the role of the Epithelial-Mesenchymal plasticity in prostate cancer progression.

Poster: Hu Q, Sweeney K, Russell P, Williams E, Nelson C, Hollier B. Non-Invasive photoacoustic and ultrasound monitoring of prostate tumour responses to androgen targeted therapies.

Poster: Panchadsaram J, Tevz G, Stylianou N,  Hollier B, Nelson C, Clements J, Batra J. Allele specific regulation of IRX4 expression by androgens in prostate cancer.

Poster: Ratther E, Sweeney K, Stylianou N, Tevz G, Nelson CC, Williams ED, Hollier BG, Investigating the role of neuroendocrine transdifferentiation in the progression to castration resistant prostate cancer.

5th Annual Translational Bioinformatics Conference, Tokyo, Japan, 7 – 9 November 2015

Poster: Seim I, Thomas PB, Lai J, Jeffery PL, Chopin LK. Re-analysis of RNA-sequencing data reveals cancer-specific chimaeric transcripts.

TRI Friday Seminar Series, 6 November 2015

Oral: Panchadsaram J. The role of 5p15 locus in prostate cancer risk and progression.

The 35th Congress of the Société International d'Urologie (SIU 2015), Melbourne, 15-18 October 2015

Poster: Rhee H, Gunter J, Jovanovic L, Williams E, Hollier B, Vela I, Nelson C. Update on Androgen Deprivation Therapy and Adjuvant Metformin (ADMET) Trial for Men with Treatment Naïve Metastatic Prostate Cancer.

Epithelial-to-Mesenchymal Transition (EMT) Queensland Symposium, Brisbane, 16 October 2015

Poster: Rhee H. The use of circulating tumour cells in delivery of precision medicine.
Oral: Hollier BG. Targeting epithelial plasticity for new prostate cancer therapies,

The 2nd Thomas Ashworth Symposium on Circulating Tumour Cells, Melbourne, 12 October 2015:

Invited speaker: Rhee H, Gunter J, Jovanovic L, Williams E, Hollier B, Vela I, Nelson CC. Enrichment and propagation of circulating tumour cells in men with hormone naïve metastatic prostate cancer.

Invited speaker: Soekmadji C. Extracellular vesicles for monitoring treatment response in advanced prostate cancer.

The EMT International Association (TEMTIA) Conference, Melbourne, 11 – 14 October 2015:

Oral and Poster: Stylianou N. The mesenchymal-to-epithelial reverting transition (MErT) is enriched in lethal metastatic castrate resistant prostate cancer and correlates with an overall poor prognosis across multiple cancers.

Poster: Sweeney K, Stylianou N, Tevz G, Pirlo K, Fazli L, Gleave M, Gunter J, Williams ED, Nelson CC, Hollier BG. Elucidating the role of ZEB1 in metastatic castration resistant prostate cancer.

Poster: Sarkar P, Gunter J, Lubik A, Stylianou N, Hollier B, Pollak M, Williams E, Nelson C. Insulin increases invasion in androgen deprived prostate cancer cells by activating EMT like changes.

Poster: Upadhyaya A, Stylianou N, Hollier B, Williams ED. Targeting Epithelial to Mesenchymal Transition (EMT) to modulate prostate cancer cell chemoresistance.

Poster: Fuhrman-Luck R, Kryza T, Hastie M, Stoll T, Ho B, Lehman M, Kleifeld O, Gorman J, Loessner D, Clements J, Identification of a novel protease activator of transforming growth factor β1 signalling in the prostate tumour microenvironment.

TRI Friday Seminar Series, 9 October 2015

Oral: Matin F. MiRNAs in Plasma: Potentially Minimally Invasive Biomarkers for the Detection of Aggressive Prostate Cancer

9th General Meeting of the International Proteolysis Society Conference, Penang, Malaysia, 4–8 October 2015

Poster: Kryza T, Tevz G, McPherson S, Lehman M, Stephens C, Hollier B, Nelson C, Clements J. Dysregulation of the proteolytic network in prostate cancer cells after androgen deprivation and androgen-targeting therapies

The Early Career Forum of the 9th General Meeting of the International Proteolysis Society Conference, Penang, Malaysia, 4–8 October 2015

Oral and Poster: Kryza T. Modulation of protease expression in prostate cancer cells after androgen deprivation/anti-androgen therapies.

Oral: Fuhrman Luck R. Global profiling of kallikrein-related peptidase 4 (KLK4) substrates and downstream regulated genes in prostate cancer (Awarded best ECR/ student oral presentation)

TRI Friday Seminar Series. 2 October 2015

Oral: Walpole C. Characterisation of benign and primary tumour derived novel epithelial prostate cell lines. 

Poster: Maugham M, Thomas, P, Crisp, G, Gregory, L, Jeffery, P, Chopin, L. A pilot study investigating the ghrelin receptor as a treatment target for prostate cancer. Brisbane Cell and Developmental Biology meeting, Brisbane, 2 October 2015.

Oral: Hollier BG. Targeting epithelial plasticity for new prostate cancer therapies. TRI Cancer Seminar Series, Brisbane, 1 October 2015.

Poster:  Kryza T, Tevz G, McPherson S, Lehman M, Stephens C, Hollier B, Nelson C, Clements J. Dysregulation of the proteolytic network in prostate cancer cells after androgen deprivation and androgen-targeting therapies, 6th International Symposium on Kallikreins and Kallikrein-Related Peptidases, Brisbane, 28 September – 1 October 2015.

The Deutscher Akademischer Austauschdienst (DAAD) Workshop, Brisbane, 24 - 25 September 2015:

Oral: Bock N. A 3D In Vitro Model Reflecting the Androgen Deprivation State In Prostate Cancer.

Oral: Kryza T. Anti-Androgen therapies modulate protease expression in prostate cancer cells.

Oral: Williams E. Experimental approaches to performing cellular assays in 3D development analysis and imaging. TRI Seminar ‘Media Matters’, Brisbane, 22 September 2015.

International Conference on Relaxin and Related Peptides, Kuching, Malaysia, 20 – 24 September 2015

Poster: Tevz G, McGrath S, Rockstroh A, Jeet V, McPherson S, Lehman M, Lai J, Batra J, An J, Williams E, Nelson C. Identification of a novel fusion transcript between human relaxin-1 (RLN1) and human relaxin-2 (RLN2) in prostate cancer. 7th .

TRI Friday Seminar Series, 18 September 2015.

Oral: Thomas P. Control of prostate tumour growth by the long-coding RNA GHSROS.

The Annual TRI Poster Symposium, Brisbane, 17 September 2015:

Oral: Gunter J. Targeting metabolic drivers of prostate cancer resistance and survival. (Awarded best MCR presentation).

Oral: Tse B. Multimodal hyperbranched polymers targeting prostate specific membrane antigen (PSMA) for imaging of prostate cancer. (Awarded best ECR presentation).

Oral: Panchadsaram J. An allele-dependent regulation of IRX4 by androgens in prostate cancer. (Awarded best student oral presentation).

Oral: Matin F. MicroRNAs in Plasma: Potential minimally invasive biomarkers for the detection of aggressive prostate cancer. (Awarded third prize in the student oral presentations).

Poster: Lisle J. Proteolysis of the EphB4 receptor in prostate cancer; Does it produce bioactive cleavage fragments. (Awarded best student poster).

Poster: Stylianou N. MErT is enriched in lethal metastatic castrate resistant prostate cancer and correlates with an overall poor prognosis across multiple cancers. (Awarded runner up student poster)

Poster: Kryza T. Modulation of protease expression in prostate cancer cells after androgen deprivation. (Awarded best ECR poster)

Poster: Sweeney K, Stylianou N, Tevz G,  Pirlo K, Upadhyaya A, Ratther E, Lehman M, Fazli L, Gleave M, Gunter, J, Williams ED, Nelson CC, Hollier BG. Elucidating the role of ZEB1 in metastatic castration resistant prostate cancer. (Awarded second best ECR poster)

Poster: Thomas P. Targeting the long non-coding RNA GHSROS, a mediator of prostate cancer tumour growth, with short antisense oligonucleotides.
Poster: Maugham M, Thomas P, Crisp G, Gregory L, Jeffery P, Chopin L. A pilot study investigating the ghrelin receptor as a treatment target for prostate cancer.

Poster: Ratther E, Sweeney K, Stylianou N, Tevz G, Nelson CC, Williams ED, Hollier BG, Investigating the role of neuroendocrine transdifferentiation in the progression to castration resistant prostate cancer.

Poster: Bock N, Kryza T, Loessner D, Clements JA, Hutmacher DW, Developing an in vitro 3D bone metastasis model for advanced prostate cancer.

4th TERMIS World Congress, Boston, USA, 8-11 September 2015

Poster: Bock N, Loessner D, Clements JA, Hutmacher DW. A tissue engineered bone construct as a 3D metastasis colonization model.

TRI Friday Seminar Series, 4 September 2015

Oral: Sagar Y. The involvement of Glutathione Transferases and exosomes in regulating the progression and metastasis of Prostate Cancer. 

The TRI Cancer Seminar Series, Brisbane, 3 September 2015

Oral: Thomas P. The ghrelin receptor antisense long non-coding RNA, GHSROS, regulates prostate cancer growth and survival and can be targeted with a locked antisense oligonucleotide.

Oral: Jeet V. Investigating the role of a potential angiogenic target, YKL40, for the treatment of metastatic prostate cancer.

Endocrine Society of Australia/Society for Reproductive Biology Annual Scientific Meeting, Adelaide, 24 – 26 August 2015

Oral: Soekmadji C, Riches J, Wang C, Ruelcke J, McPherson S, Russell PJ, Hill MM, Nelson CC. Extracellular vesicle-mediated growth in androgen-deprived prostate cancer cells. 

The Second Prostate Cancer World Congress, Cairns, 17 – 21 August 2015

Invited speaker: Nelson C. Adaptive response to androgen targeted therapies.

Invited speaker: Ling P, Adipocytes promote prostate cancer stem cell self-renewal through amplification of the cholecystokinin autocrine loop.

Invited speaker: Vela I, Use of organoid in vitro culture technology for precision medicine in prostate cancer.

Invited speaker: Gunter JH. Targeting metabolic drivers of prostate cancer resistance and survival.

Invited speaker: Bock N. Convergence of regenerative medicine and systems biology to develop clinically relevant models of prostate cancer.

Oral and Poster: Rockstroh A, Pokorny MR, Walker C, Lehman ML, Nelson CC, Y-Box Binding Protein 1 (YB-1), a key regulator of Androgen Receptor (AR) signalling.

Oral and Poster: Jeet V, Rockstroh A, Lehman M, Nelson C, Investigating the role of a potential angiogenic target, YKL40, for the treatment of metastatic prostate cancer.

Oral and Poster: Tse B, Fuchs AV, Pearce A, Yeh MC, Fletcher N, Huang SS, Heston WDW, Whittaker AK, Thurecht KJ, Russell PJ. Multimodal hyperbranched polymers for prostate cancer theranostics.

Oral and Poster: Thomas PB, Walpole CM, Jeffery PL, Jovanovic L, Herington AC, Nelson CC, Whiteside EJ, Veedu RN, Seim I, Chopin LK. The ghrelin receptor antisense long non-coding RNA GHSROS in prostate cancer growth and survival. (Awarded first prize poster in Translational Science category).

Oral and Poster: Sweeney K, Stylianou N, Tevz G, Pirlo K, Upadhyaya A, Lehman M, Fazli L, Gleave M, Gunter J,  Williams ED, Nelson CC, Hollier BG. Elucidating the role of ZEB1 in metastatic castration resistant prostate cancer.

Oral and Poster: Stylianou N, Jovanovic L, Wang C, Lehman ML, Sadowski MC, Williams E, Gunter J, Nelson CC,  Hollier BG. The mesenchymal-to-epithelial reverting transition is enriched in metastatic castration resistant prostate cancer and correlates with poor survival.

Oral and Poster: Bock N, Loessner D, Hutmacher DW, Clements JA. A 3-D in vitro model reflecting the androgen deprivation state in prostate cancer bone metastasis.

Oral and Poster: Rhee H, Gunter J, Jovanovic L, Williams E, Hollier B, Vela I, Nelson C. Enrichment and propagation of circulating tumour cells in men with hormone naïve metastatic prostate cancer.

Poster: Volpert M, Tse B, Ratther E, Stylianou N, Nouri M, Roshan-Moniri M, Butler M, Caradec J, Gregory-Evans C, Lehman M, Takhar M, Erho N, Alshalafa M, Davicioni E, Jenkins R, Karnes J, Den R, Fazli L, Gleave M, Williams E, Rennie P, Buttyan R, Gunter J, Russell P, Nelson C, Hollier B. Targeting neuropilin-1 to inhibit prostate cancer metastasis and therapy resistance.

Poster: Ling P, Liu J, Polysaccharopeptide enhanced the anti-cancer effect of gamma-tocotrienol through activation of AMPK.

Poster: Walpole C, Rae F, Jovanovic L, Odorico D, McLennan E, Lawrence M, Nelson C, Williams E, Batra J, Clements J. Characterisation of novel primary tumour derived epithelial prostate cancer cell lines.

Poster: Wagholikar A, Ding H. Remote monitoring of Advanced Prostate Cancer patients after Androgen Deprivation Therapy using Mobile Health Technology: Opportunities for novel care models.

Poster: Panchadsaram J, Tevz G, Stylianou N, Hollier B, Nelson CC, Clements J, Batra J. A Multiple Nucleotide Length Polymorphism (MNLP) mediates androgen regulation of IRX4 in prostate cancer.

Poster: An J, Lai J, Wood DLA, Sajjanhar A, Wang C, Tevz G, Lehman ML, Nelson CC. DeepView: A genome browser for simultaneous visualization of raw strand specific RNAseq reads and UCSC genome browser custom tracks.

Poster: Fuhrman-Luck R, Kryza T, Hastie M, Stoll T, Kleifeld O, Ho B, Lehman M, Rockstroh A,  Nelson C, Gorman J, Loessner D, Clements J. Kallikrein-related peptidase 4 induces tumour microenvironment alterations that support tumour growth.

Poster: Soekmadji C, Ruelcke J, Wang C, Riches JD, McPherson S, Russell PJ, Hill MM, Jenster G, Nelson CC. Extracellular vesicles mediate paracrine signalling in androgen deprived prostate cancer.

Poster: Maharaj M, Mertens-Walker I, Croll T, Lisle J, Stephens C, Walsh T, Herington A, Stephenson S-A. SUMOylation regulates stability and function of the receptor tyrosine kinase EphB4.

Poster: Mosaad EMO, Chambers K, Clements J, Doran M. Rethinking stromal cells contribution in the drug screening approach of prostate cancer.

Poster: Pandey S, Walpole C, Cabot PJ, Shaw PN, Batra J, Hewavitharana AK. Carica papaya leaf juice extracts have selective anti-proliferative responses in prostatic disease.

Poster: Tevz G, Hossain AM, Bock N, Jeet V, Bathgate RA, Williams E, Lehman M, Hutmacher DW,  Wade JD, Nelson CC. Impeding the adaptive response of prostate cancer to androgen targeted therapies with relaxin receptor antagonist.

Poster: Kryza T, Tevz G, McPherson S, Lehman M, Stephens C, Hollier B, Nelson C, Clements J. Modulation of protease expression in prostate cancer cells after androgen deprivation.

Poster: Ratther E, Sweeney K, Stylianou N, Nelson CC, Williams ED, Hollier BG. Investigating the role of neuroendocrine transdifferentiation in the progression to castration resistant prostate cancer.

Poster: Gunter JH, Lee W, Philp LK, Sarkar P, Hollier BG, Sadowski M, Lehman M, Nelson CC. Insulin increases apoptotic resistance in prostate cancer cells but are sensitised by metformin.

Poster: Philp LK, Gunter JH, Sadowski MC, Tevz G, Lehman M, Otvos L, Nelson CC. Leptin receptor antagonist Allo-Aca prevents migration invasion and modifies lipogenesis pathways in prostate cells.

Poster: Sadowski MC, Gunter JH, Gupta R, Blanksby SJ, Nelson CC. Investigation of deregulated lipid metabolism in advanced prostate cancer.

Poster: Yeadon T, Australian Prostate Cancer BioResource 2015.

TRI Friday Seminar Series, 7 August 2015

Oral: Bock N. Developing an In Vitro 3D Bone Metastasis Model for Castrate Resistant Prostate Cancer.

The Princess Alexandra Hospital Health Symposium, Brisbane, 4-7 August 2015

Abstract: Stegeman S, Klein K, Moya L, Practical Consortium, Spurdle A, Clements J, Batra J. A large scale association analysis of miRSNPS with prostate cancer. (Young Investigator Award Abstract Finalist).

Poster: Matin F, Moya L, Jeet V, Clements J, Batra J. MicroRNAs in plasma: Potential minimally invasive biomarkers for the detection of aggressive prostate cancer.

Poster: Panchadsaram J, Tevz G, Stylianou N, Hollier B, Nelson C, Williams ED, Clements J, Batra J, An allele-dependent regulation of IRX4 by androgens in prostate cancer.

Poster: Ryan SL, Baird AM, O’Byrne K, Davies A. Elucidating drug resistance mechanisms using 2D and 3D culture systems.

Poster: Srinivasan S, Stephens C, Clements J, Batra J. Functional validation of PSA coding variants associated with prostate cancer risk.

 TRI Friday Seminar Series, 24 July 2015

Oral: Ratther E, Characterising neuroendocrine trans-differentiation in the progression to castration resistant prostate cancer.

Annual Postgraduate Student Research Symposium, Melbourne, 23 July 2015.

Oral: Levrier C, Sadowski MC, Nelson CC, Davis RA, Mechanism of action studies in prostate cancer cells of new compounds isolated from an Australian endemic rainforest tree, CTx

The 6th International PacRim Breast and Prostate Cancer Meeting, Washington State, USA, 20 – 24 July 2015:

Invited speaker: Nelson C, Is it possible to prevent prostate cancer?
Invited speaker: Batra J, A large scale association analysis of miRSNPs with prostate cancer.
Poster: Kryza T, Tevz G, McPherson S, Lehman M, Stephens C, Hollier B, Nelson C, Clements J. Androgen deprivation leads to up regulation of proteases involved in tumor invasion and metastasis.

Australian New Zealand Society for Mass Spectrometry 25th Conference, Brisbane, 19 – 22 July 2015.

Poster: Gupta R, Marshall DL, Sadowski M, Blanksby SJ. Shotgun Lipidomics of prostate cancer cells using ESI-MS Shimadzu 8050.

TRI Seminar, Brisbane, 26 June 2015

Oral: Tevz G, Identification of a novel fusion transcript between human relaxin-1 (RLN1) and human relaxin-2 (RLN2) in prostate cancer.

ASMR Postgraduate Student Conference, Brisbane, 27 May 2015

Oral: Levrier, C, Sadowski, MC; Nelson CC, Davis RA. Mechanism of action studies in prostate cancer cells of new compounds isolated from an Australian endemic rainforest tree, (First prize in oral competition)

TRI Seminar, Brisbane, 22 May 2015

Oral: Kryza T, Involvement of kallikrein-related peptidase 4 and PAR1 in prostate fibroblast activation

TRI Cancer Seminar, Brisbane, 14 May 2015

Oral: Bock N, Developing an in vitro 3D bone metastasis model for castrate resistant prostate cancer

Virtual Event, 5–6 May 2015

Invited speaker: Lehman M, A case for RNAseq in prostate cancer research, SelectBio Advances in Next Generation Sequencing

The 1st Australian Cancer and Metabolism Meeting, Sydney, 29 April–1 May 2015:

Invited speaker: Sadowski M, Investigation of deregulated lipid metabolism in advanced prostate cancer.

Invited speaker: Gunter J, Insulin increases apoptotic resistance and metabolic capacity in prostate cancer cells that is inhibited by Metformin.

Poster: Philp LK, Sadowski MC, Liberio MS, Tevz G, Lehman M, Gunter JH, Otvos L, Nelson C. Leptin receptor antagonist, allo-aca, prevents leptin-stimulated migration of androgen-deprived prostate cancer cells.

Poster: Wang Q, Hardie R-A, Hoy AJ, van Geldermalsen M, Gao D, Fazli L, Sadowski MC, Balaban S, Schreuder M, Nagarajah R, Wong J J-L, Metierre C, Pinello N, Otte NJ, Lehman ML, Gleave M, Nelson CC, Bailey CG, Ritchie W, Rasko JEJ, Holst J, Inhibition of ASCT2-mediated glutamine uptake blocks prostate cancer growth.

International Society for Extracellular Vesicles (ISEV) 2015 Annual Meeting, Washington DC, USA, 23–26 April 2015

Oral: Soekmadji C, Russell PJ, Riches JD, Ruelcke J, Wang C, McPherson S, Hill MM, Jenster G, Nelson CC. Androgen stimulated extracellular vesicles regulate cellular proliferation in androgen deprived prostate cancer cells

Inaugural John Fitzpatrick Irish Prostate Cancer Conference, Dublin, Ireland, 23–25 April 2015

Invited speaker: Nelson C. Targeting Adaptive Responses to Androgen Targeted Therapies

TRI Cancer Seminar, Brisbane, 16 April 2015

Oral: Sadowski M, Lubik AA, Locke JA, Hendy S, Moeinvaziri F, Davies J, Nelson CC. Inhibition of fatty acid synthase suppresses androgen signaling in LNCaP cells

The Urological Society of Australia and New Zealand (USANZ) Annual Scientific Meeting, Adelaide, 11–14 April 2015

Podium: Vela I. Development of novel metastatic prostate cancer cell lines by “organoid” in vitro culture technology.

Podium: Rhee H. Clinical application of biomarkers in prostate cancer in men with metabolic syndrome project: clinical evaluation of prognostic and metabolic benefits of Metformin in prostate cancer.

Poster: Rhee H, Heathcote P, Wood S, Greenslade S, Russell P, Nelson C, Thomas P. Clinical application of biomarkers in prostate cancer in men with metabolic syndrome project: Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in diagnosing localised prostate cancer.

The 15th Australian Cell Cycle Meeting, Sydney, 30 March–1 April 2015

Poster: Sadowski MC, Lubik AA, Locke JA, Hendy S, Moeinvaziri F, Davies J, Nelson CC. Inhibition of fatty acid synthase suppresses androgen signaling in LNCaP cells.

Oral & Poster: Levrier C, Sadowski MC, Davis RA, Nelson CC.  Mechanism of action studies in prostate cancer cells on new compounds isolated from an Australian endemic rainforest tree.

TRI Seminar, Brisbane, 27 March 2015

Oral: Maugham M, The ghrelin receptor as a treatment target for prostate cancer.

Eskitis Student Symposium, Brisbane, 26 - 27 March 2015.

Oral and Poster: Levrier C, Sadowski MC, Davis RA, Nelson CC. Mechanism of action studies in prostate cancer cells on new compounds isolated from an Australian endemic rainforest tree. (First prize in poster competition)

PeCan prostate cancer network meeting, Sydney, 26 March 2015

Invited speaker: Nelson C. Team science to create new therapies.

The Cure Cancer Australia Foundation Symposium, Sydney, 24–25 March 2015:

Hollier BG. Targeting neuropilin-1 to inhibit prostate cancer metastasis and therapy resistance.
Batra J. Understanding the genetics of prostate cancer.

Advanced Prostate Cancer Consensus Conference, St Gallen Switzerland, 12–14 March 2015.

Invited conference attendance: Nelson C.

TRI Seminar, Brisbane, 6 March 2015

Oral: Upadhyaya A. Targeting EMT to modulate prostate cancer cell chemoresistance.

The 97th Annual Meeting of the Endocrine Society (ENDO 2015), San Diego,   4 – 8 March 2015

Oral: Sadowski MC, Lubik AA, Locke JA, Hendy S, Moeinvaziri F, Davies J,  Nelson CC, Inhibition of fatty acid synthesis suppresses androgen receptor signaling.

Poster: Gunter JH, Lee W, Philp L, Sarkar P, Hollier B, Sadowski M, Lehman M, Nelson CC. Insulin increases apoptotic resistance and metabolic capacity in prostate cancer cells, that is inhibited by Metformin.

Poster: Sadowski MC, Rockstroh A, Soekmadji C, McPherson SJ, Tevz G, Gunter JH, Jeet V, Nelson CC, Phenotypic and molecular analysis of androgen receptor signalling in the DuCaP prostate cancer cell line, (1st place Presidential Poster Competition).

Poster: Philp LK, Sadowski MC, Liberio MS, Tevz G, Lehman M, Gunter JH, Otvos L, Nelson C. Leptin receptor antagonist, allo-aca, prevents leptin-stimulated migration of androgen-deprived prostate cancer cells.